Category: 1004-17-7

Adding a certain compound to certain chemical reactions, such as: 1004-17-7, 2-Methylpyrimidine-4-carbaldehyde, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, 1004-17-7, blongs to pyrimidines compound. Product Details of 1004-17-7

Step A 3-(2-Methyl-pyrimidin-5-yl)-propenal (2-2) To a solution of 4-formyl-2-methylpyrimidine [2-1, 2 g, 16.4 mmol; for preparation, see Smith, S. Q. et al, J. Heterocyclic Chem. 28: 1281 (1991)] in methylene chloride (15 mL) was added (formylmethylene)triphenylphosphorane (5.98g, 19.6 mmol). The solution was heated at reflux for 4 h, cooled to room temperature, and solvents evaporated. The residue was chromatographed on silica gel (30% EtOAc/chloroform to 50 EtOAc/50 chloroform/5 methanol) to give the aldehyde 2-2 as a yellow solid. TLC Rf=0.39 (70 chloroform/25 EtOAc/5 MeOH). 1H NMR (400 MHz, CDCl3) delta 9.74 (d, 1H, J=7 Hz), 8.83 (s, 2H), 7.41 (d, 1H, J=7 Hz), 6.81 (dd, 1H, S=6 Hz, 15 Hz), 2.77 (s, 3H).

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route,1004-17-7, its application will become more common.

Reference:
Patent; Merck & Co., Inc.; US6410526; (2002); B1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Adding a certain compound to certain chemical reactions, such as: 1004-17-7, 2-Methylpyrimidine-4-carbaldehyde, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, Quality Control of 2-Methylpyrimidine-4-carbaldehyde, blongs to pyrimidines compound. Quality Control of 2-Methylpyrimidine-4-carbaldehyde

4-Dimethoxymethyl-2-methyl-pyrimidine (4.5 g, 26.7 mmol) was added to a solution of HBr (48% in H2O, 10 niL) and stirred at room temperature for 2 hours. It was then diluted with water and washed with diethylether (2x). The aqueous layer was carefully neutralized with saturated sodium carbonate and extracted with ethyl acetate (2x). The combined extracts were dried over MgSO4. 2-Propanol (100 mL) was added. To this solution, aniline (2.5 mL, 26.7 mmol) was added and followed with diphenylphosphite (5.1 mL, 26.7 mmol). The reaction mixture was stirred at room temperature overnight and then concentrated. The residue was purified on silica gel column with 20% ethyl acetate/CH2Cl2 to give a yellow solid (3.3 g, 29% for 2 steps) as the desired product. MS (ESP+) m/z 432.2 (M + 1).

The synthetic route of 1004-17-7 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; BIOGEN IDEC MA INC; WO2006/26305; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

1004-17-7, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.1004-17-7, name is 2-Methylpyrimidine-4-carbaldehyde, molecular formula is C6H6N2O, molecular weight is 122.1246, as common compound, the synthetic route is as follows.

Intermediate 10 (0516) (S)-Methyl 4-(2-chloro-5-methylpyridin-4-yl)-l-(2-(((2-methylpyrimidin-4- l)methyl)amino)propyl)-lH-pyrrole-2-carboxylate (0517) (0518) 2-methylpyrimidine-4-carbaldehyde (96 mg, 0.79 mmol) was added to (5)-methyl l-(2- aminopropyl)-4-(2-chloro-5-methylpyridin-4-yl)-lH-pyrrole-2-carboxylate (0519) dihydrochloride (Intermediate 3; 250 mg, 0.66 mmol) in DCM (10 mL) at 25C under nitrogen. After stirring at 40C for 3 hours, sodium triacetoxyborohydride (278 mg, 1.31 mmol) was added. The resulting mixture was stirred at 25 C for 12 hours. The reaction mixture was quenched with saturated NaHC03 (20 mL), extracted with DCM (3 x 50 mL) and dried over Na2S04, filtered and evaporated to afford a residue. The crude product was purified by flash silica chromatography (elution gradient 0 to 5% MeOH in DCM). Pure fractions were evaporated to dryness to afford (5)-methyl 4-(2-chloro-5-methylpyridin-4- yl)- 1 -(2-(((2-methylpyrimidin-4-yl)methyl)amino)propyl)- 1 H-pyrrole-2-carboxylate (Intermediate 10; 130 mg, 47.8 %) as a solid, m/z (ES+), [M+H]+ = 414.

Statistics shows that 1004-17-7 is playing an increasingly important role. we look forward to future research findings about 2-Methylpyrimidine-4-carbaldehyde.

Reference:
Patent; ASTRAZENECA AB; WARD, Richard, Andrew; JONES, Clifford, David; FERON, James, Lyman; (80 pag.)WO2017/80980; (2017); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

1004-17-7, In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. 1004-17-7, name is 2-Methylpyrimidine-4-carbaldehyde, the common compound, a new synthetic route is introduced below.

99. (+)-2- 3,4-trans)-4-methyl-l-q2-methylpyrimidin-4- yl)methyl)pyrrolidin-3-yl)-7-ftetrahvdro-2H-pyran-4-yl)imidazo[5,l- f] ri,2,41triazin-4(3H)-one [1058] To a stirred solution of (-)-2-((3,4-trans)-4-methylpyrrolidin-3-yl)-7- (tetrahydro-2H-pyran-4-yl)imidazo[5,l- J[l,2,4]triazin-4(3H)-one (150 mg, 0.49 mmol) in MeOH (10 mL) was added 2-methylpyrimidine-4-carbaldehyde (66 mg, 0.54 mmol) at RT under argon atmosphere. After being stirred for 2 h, NaCNBH3 (92 mg, 1.47 mmol) was added to the reaction mixture and stirring was continued for another 16 h at RT. The volatiles were evaporated under reduced pressure. The residue was diluted with ice-cold water (15 mL) and extracted with DCM (2 x 20 mL). Combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to obtain the crude product. The crude material was purified by silica gel column chromatography and then further purified by preparative HPLC to afford (+)-2-((3 ,4-trans)-4-methyl- 1 -((2-methylpyrimidin-4-yl)methyl)pyrrolidin-3 – yl)-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,l- J[l,2,4]triazin-4(3H)-one (50 mg, 25%) as an off-white solid; 1H-NMR (DMSO d6, 400 MHz): delta 11.72 (bs, 1H), 8.64 (d, 1H), 7.67 (s, 1H), 7.32 (d, 1H), 3.97-3.93 (m, 2H), 3.84-3.68 (m, 2H), 3.52-3.47 (m, 2H), 3.41-3.37 (m, 1H), 3.06-2.38 (m, 4H), 2.69-2.65 (m, 2H), 2.58 (s, 3H), 2.37-2.32 (m, 4H), 1.09 (d, 3H); Mass (ESI): 410 [M++l]; LC-MS: 98.26%; 410.3 [M++l]; (column; X-bridge C-18, (50×3.0 mm, 3.5mu); RT 2.31 min. 5mM NH4OAc: ACN; 0.8 ml/min); HPLC (purity): 99.24%; (column; Eclipse XDB C-18, (150×4.6 mm, 5.0mu); RT 7.50 min. 5mM NH4OAc (Aq): ACN; 1.0 ml/min; Chiral HPLC: 100%, R, = 10.36 min (Chiralpak IA, 250 x 4.6mm, 5mu; mobile phase (A) 0.1% TEA in n- Hexane (B) IPA (A: B : 75:25); flow Rate: 1.00 mL/min); Optical rotation [a]D2: +69.96 (c = 0.25, DCM); TLC: 10% MeOH/DCM (Rf: 0.4).

Statistics shows that 1004-17-7 is playing an increasingly important role. we look forward to future research findings about 2-Methylpyrimidine-4-carbaldehyde.

Reference:
Patent; ENVIVO PHARMACEUTICALS, INC.; RIPKA, Amy; SHAPIRO, Gideon; MCRINER, Andrew, J.; BURSAVICH, Matthew, Gregory; WO2013/142269; (2013); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia